drugset / Trial / NCT01832571
SCOPE: Strategies to Combine PrEP With Prevention Efforts
Withdrawn
FHI 360
Family Health Options Kenya · collabGilead Sciences · collabInstitute of Tropical Medicine · collabSex Workers Outreach Programme · collabUniversity of North Carolina, Chapel Hill · collab
NaSingle-groupOpen-label
Summary
This pilot, open-label, prospective study will determine the feasibility of integrating pre-exposure prophylaxis (PrEP) into existing HIV prevention programs for female sex workers and if women who are enrolled in those programs will adhere to the daily PrEP regimen of Truvada®. This study will enroll 500 HIV antibody negative female sex workers in Eldoret and Nairobi, Kenya.
Timeline
- Start
- 2013-06
- Primary completion
- 2013-07
- Completion
- 2013-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenofovir | Small molecule | 200 mg | Oral |
| Subject | Tenofovir | Small molecule | 300 mg | Oral |